Using genetics to enable studies on the prevention of alzheimer's disease

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 2, 2013, Pages 177-185

  Crenshaw, D G ^a   Gottschalk, W K ^a   Lutz, M W ^a   Grossman, I ^b   Saunders, A M ^a   Burke, J R ^a   Welsh Bohmer, K A ^a   Brannan, S K ^c   Burns, D K ^d   Roses, A D ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b IsraGene Ltd   (Israel)

^c Takeda Pharmaceuticals International Inc   (United States)

^d Zinfandel Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRESENILIN 1; PRESENILIN 2; PROTEIN PRECURSOR; RIVASTIGMINE; ROSIGLITAZONE;

ALGORITHM; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CHROMOSOME 19; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DNA SEQUENCE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROENCEPHALOGRAM; EPISODIC MEMORY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETICS; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; LEARNING; LOW DRUG DOSE; LOW RISK POPULATION; MILD COGNITIVE IMPAIRMENT; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PHENOTYPE; PHYLOGENETIC TREE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COGNITION; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84872686057     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.222     Document Type: Article

References (69)

1. Bateman, R.J. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1 (2011).
2. Ashford, J.W. & Mortimer, J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. J. Alzheimers Dis. 4, 169-177 (2002).
3. Alzheimer's Association. 2012 Alzheimer's disease facts and fgures. Alzheimers Dement. 8, 131-168 (2012).
4. Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337-1342 (1998).
5. Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H.M. forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186-191 (2007).
6. Gingrich, N. & Egge, R. Developing a national Alzheimer's strategy equal to the epidemic. Alzheimers Dement. 3, 239-242 (2007).
7. Khachaturian, Z.S. Prospects for designating Alzheimer's disease research a national priority. Alzheimers Dement. 7, 557-561 (2011).
8. Birks, J. & Harvey, R. Donepezil for dementia due to Alzheimer's disease (Review). Cochrane Database Syst. Rev., CD001190 (2009).
9. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716 (2010).
10. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., CD005593 (2009).
11. McShane, R. & Schneider, L.S. Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimers Dement. 1, 67-71 (2005).
12. Salomone, S., Caraci, F., Leggio, G.M., fedotova, J. & Drago, F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73, 504-517 (2012).
13. Albert, M.S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279 (2011).
14. Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: A National Imperative http://www.alz.org/documents-custom/trajectory.pdf (2010).
15. Martin, B.K. et al. Cognitive function over time in the Alzheimer's Disease Anti-infammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896-905 (2008).
16. Lyketsos, C.G. et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1888 (2007).
17. Espeland, M.A. et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2959-2968 (2004).
18. Rapp, S.R. et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2663-2672 (2003).
19. Shumaker, S.A. et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
20. Snitz, B.E. et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302, 2663-2670 (2009).
21. Andrieu, S., Ousset, P.J., Coley, N., Ouzid, M., Mathiex-fortunet, H. & Vellas, B. GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr. Alzheimer Res. 5, 406-415 (2008).
22. Meinert, C.L. & Breitner, J.C. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-infammatory Prevention Trial (ADAPT). Alzheimers Dement. 4, S7-S14 (2008).
23. Vellas, B. et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 11, 851-859 (2012).
24. Temple, R. Enrichment of clinical study populations. Clin. Pharmacol. Ther. 88, 774-778 (2010).
25. McKhann, G.M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
26. Goodsaid, F.M. & Mendrick, D.L. Translational medicine and the value of biomarker qualifcation. Sci. Transl. Med. 2, 47ps44 (2010).
27. Roses, A.D. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J. Alzheimers Dis. 9, 361-366 (2006).
28. Corneveaux, J.J. et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verifed individuals. Hum. Mol. Genet. 19, 3295-3301 (2010).
29. Eisenberg, D.T., Kuzawa, C.W. & Hayes, M.G. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am. J. Phys. Anthropol. 143, 100-111 (2010).
30. Mayeux, R. et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338, 506-511 (1998).
31. Roses, A.D. et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 10, 375-384 (2010).
32. Linnertz, C. et al. Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS ONE 7, e30994 (2012).
33. Roses, A. et al. TOMM40 "523" polyT allele frequencies in diferent ethnic groups. Alzheimers Dement. 4, e41 (2010).
34. Green, R.C. et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287, 329-336 (2002).
35. Gureje, O. et al. APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians. Ann. Neurol. 59, 182-185 (2006).
36. Maestre, G. et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann. Neurol. 37, 254-259 (1995).
37. Tang, M.X. et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279, 751-755 (1998).
38. Ashford, J.W. APOE genotype Effects on Alzheimer's disease onset and epidemiology. J. Mol. Neurosci. 23, 157-165 (2004).
39. Corder, E.H. et al. Protective Effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180-184 (1994).
40. Johnson, S.C. et al. The Effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement. 7, 456-465 (2011).
41. Caselli, R.J. et al. Longitudinal modeling of cognitive aging and the TOMM40 Effect. Alzheimers Dement. 8, 490-495 (2012).
42. Hayden, K.M. et al. A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. Alzheimers Dement. 8, 381-388 (2012).
43. Farrer, L.A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
44. Asin, K.E. et al. Changes in fMRI resting state functional connectivity in rats after acute and repeat dosing with pioglitazone. Alzheimer's Association International Conference, Vancouver, Canada, 14-19 July 2012.
45. Zhang, N. et al. Mapping resting-state brain networks in conscious animals. J. Neurosci. Methods 189, 186-196 (2010).
46. Wierenga, C.E. & Bondi, M.W. Use of functional magnetic resonance imaging in the early identifcation of Alzheimer's disease. Neuropsychol. Rev. 17, 127-143 (2007).
47. Landreth, G., Jiang, Q., Mandrekar, S. & Heneka, M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481-489 (2008).
48. Nicolakakis, N. & Hamel, E. The nuclear receptor PPARγ as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front. Aging Neurosci. 2, 21 (2010).
49. Nicolakakis, N. & Hamel, E. Neurovascular function in Alzheimer's disease patients and experimental models. J. Cereb. Blood Flow Metab. 31, 1354-1370 (2011).
50. Du, J., Sun, B., Chen, K., Fan, L. & Wang, Z. Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice. Biochem. Biophys. Res. Commun. 384, 357-361 (2009).
51. Mandrekar-Colucci, S., Karlo, J.C. & Landreth, G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive defcits in a murine model of Alzheimer's disease. J. Neurosci. 32, 10117-10128 (2012).
52. Pedersen, W.A., McMillan, P.J., Kulstad, J.J., Leverenz, J.B., Craft, S. & Haynatzki, G.R. Rosiglitazone attenuates learning and memory defcits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265-273 (2006).
53. Rodriguez-Rivera, J., Denner, L. & Dineley, K.T. Rosiglitazone reversal of Tg2576 cognitive defcits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 216, 255-261 (2011).
54. Searcy, J.L. et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 30, 943-961 (2012).
55. Nicolakakis, N., Aboulkassim, T., Aliaga, A., Tong, X.K., Rosa-Neto, P. & Hamel, E. Intact memory in TGf-ß1 transgenic mice featuring chronic cerebrovascular defcit: recovery with pioglitazone. J. Cereb. Blood Flow Metab. 31, 200-211 (2011).
56. Strum, J.C. et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 11, 45-51 (2007).
57. Abbatecola, A.M. et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33, 1706-1711 (2010).
58. Geldmacher, D.S., Fritsch, T., McClendon, M.J., Lerner, A.J. & Landreth, G.E. P2-408: A double-blind, placebo-controlled, 18-month pilot study of the PPAR-gamma agonist pioglitazone in Alzheimer's disease. Alzheimers Dement. 2, S366 (2006).
59. Risner, M.E. et al. Efcacy of rosiglitazone in a genetically defned population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254 (2006).
60. Sato, T. et al. Efcacy of PPAR-[gamma] agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 32, 1626-1633 (2010).
61. Watson, G.S. et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13, 950-958 (2005).
62. Harrington, C. et al. Effects of rosiglitazone-extended release as adjunctive therapy to acetylcholinesterase inhibitors over 48 weeks on cognition In APOE4-stratifed subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement. 5, e17-e18 (2009).
63. Gold, M. et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30, 131-146 (2010).
64. Wisconsin Registry for Alzheimer's Prevention (WRAP) http://www.wai.wisc. edu/research/wrap.html. Accessed 17 October 2012.
65. Joseph & Kathleen Bryan Alzheimer's Disease Research Center: Memory, Health, & Aging Project https://adrc.mc.duke.edu/index.php/research/mha- project (2012). Accessed 13 february 2012.
66. Morris, J.C. et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis. Assoc. Disord. 20, 210-216 (2006).
67. Weintraub, S. et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord. 23, 91-101 (2009).
68. Welsh-Bohmer, K.A. et al. Modifying dementia risk and trajectories of cognitive decline in aging: the Cache County Memory Study. Alzheimers Dement. 2, 257-260 (2006).
69. Grossman, I. et al. Clinical trials of AD delay of onset: enrichment by a prognostic genetic biomarker. In Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future, Vol. 2 (ed. Mandel, S) Ch. 8, figure 4 (Springer Science+Business Media B.V., 2013 (in press)).